• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Actelion Pharmaceuticals

Here are the pharma companies accused of blocking generic competition

May 17, 2018 By Sarah Faulkner

Pills

To prove a generic drug is as safe and effective as the branded version, pharmaceutical companies have to hand over upwards of 1,000 doses of the product to a generic developer. But if the manufacturer creating the generic drug cannot get its hands on enough sample, the development and testing process slows down. It could […]

Filed Under: Featured, Food & Drug Administration (FDA), Pharmaceuticals, Wall Street Beat Tagged With: Actelion Pharmaceuticals, Celgene, FDA, Gilead Sciences, GlaxoSmithKline plc, Johnson & Johnson, Novartis, Valeant Pharmaceuticals

Johnson & Johnson closes $30B Actelion buyout

June 16, 2017 By Sarah Faulkner

Actelion, Johnson & Johnson

Johnson & Johnson (NYSE:JNJ) closed its $30 billion buy of Swiss biotech firm Actelion, the company reported today. The US healthcare giant bought Actelion in an all-cash deal for $280 per share. The acquisition is expected to add $1.3 billion in sales for Johnson & Johnson in 2017, according to the company. “We are very […]

Filed Under: Featured, Mergers & Acquisitions, Pharmaceuticals, Wall Street Beat Tagged With: Actelion Pharmaceuticals, idorsia, johnsonandjohnson

Johnson & Johnson wins last regulatory nod needed for Actelion acquisition

June 9, 2017 By Sarah Faulkner

Actelion, Johnson & Johnson

Johnson & Johnson (NYSE:JNJ) said today that the European Commission approved its acquisition of Swiss biotech Actelion. The regulatory nod was the last approval needed to complete the company’s transaction. The U.S. healthcare giant added that it expects the settlement of the $30 billion all-cash tender offer on June 16. The EU commission set conditions […]

Filed Under: Featured, Pharmaceuticals, Regulatory/Compliance, Wall Street Beat Tagged With: Actelion Pharmaceuticals, johnsonandjohnson

After review of patient deaths, European regulators OK Actelion’s Uptravi

April 7, 2017 By Sarah Faulkner

After review of patient deaths, European regulators OK Actelion's Uptravi

The European Medicines Agency told doctors today that they can continue to prescribe Actelion‘s (VTX:ATLN) pulmonary arterial hypertension drug, Uptravi. The regulatory body initiated a safety review in January after 5 patients in France died and docs were asked to stop prescribing the drug. Regulators reported that their review did not suggest an increase in mortality […]

Filed Under: Featured, Mergers & Acquisitions, Regulatory/Compliance, Wall Street Beat Tagged With: Actelion Pharmaceuticals, johnsonandjohnson

Actelion shareholders OK R&D spinout

April 5, 2017 By Sarah Faulkner

Actelion, Johnson & Johnson

Actelion (VTX:ATLN) shareholders today reportedly approved spinning off the company’s early clinical assets and drug discovery branch into a new company. The move keeps Johnson & Johnson (NYSE:JNJ) $30 billion takeover on track to close in the 2nd quarter. The newly formed biopharmaceutical company will be called Idorsia Ltd and led by Actelion CEO Jean-Paul Clozel. Shares in Idorsia […]

Filed Under: Featured, Mergers & Acquisitions, Pharmaceuticals, Wall Street Beat Tagged With: Actelion Pharmaceuticals, johnsonandjohnson

Johnson & Johnson’s tender offer for Actelion snares 78% stake

March 31, 2017 By Sarah Faulkner

Actelion, Johnson & Johnson

Johnson & Johnson (NYSE:JNJ) said today that it controls nearly 78% of voting rights in its $30 billion acquisition of Swiss biotech firm Actelion (VTX:ATLN). Janssen, J&J’s Swiss subsidiary, declared the tender offer successful. The company added that based on regulatory approval proceedings, the offer is expected to settle in the 2nd quarter of this year. J&J will have […]

Filed Under: Featured, Mergers & Acquisitions, Pharmaceuticals, Wall Street Beat Tagged With: Actelion Pharmaceuticals, johnsonandjohnson

How Sanofi blew its chance with Actelion

February 16, 2017 By Sarah Faulkner

How Sanofi blew its chance with Actelion

Days before entering into exclusive takeover negotiations with Johnson & Johnson (NYSE:JNJ), Actelion (VTX:ATLN) was reportedly fielding an offer from Sanofi (NYSE:SNY). But the Swiss biotech eventually agreed to go with J&J’s $30 billion bid in an all-cash deal at the end of January. Actelion accepted the U.S. healthcare giant’s offer because it provided more certainty, Reuters reported today. The prospectus […]

Filed Under: Featured, Mergers & Acquisitions, Pharmaceuticals, Wall Street Beat Tagged With: Actelion Pharmaceuticals, johnsonandjohnson, Pfizer Inc., Sanofi-Aventis

Actelion reports income, revenue growth in FY2016

February 14, 2017 By Sarah Faulkner

After review of patient deaths, European regulators OK Actelion's Uptravi

(Reuters) – Swiss drugmaker Actelion‘s 2016 core net income rose 27 percent on accelerating sales of its newer medicines to treat deadly pulmonary arterial hypertension (PAH), it said on Tuesday. Core net income rose to 881 million Swiss francs ($877.8 million) from 693 million francs in the previous year, the company said in a statement. […]

Filed Under: Featured, MassDevice Earnings Roundup, Pharmaceuticals, Respiratory Tagged With: Actelion Pharmaceuticals

Johnson & Johnson to pay $30B for Actelion

January 26, 2017 By Sarah Faulkner

Actelion, Johnson & Johnson

After weeks of exclusive negotiations, Johnson & Johnson (NYSE:JNJ) said on Thursday that it plans to buy Swiss biotech firm Actelion (VTX:ATLN) for $30 billion in an all-cash deal. The companies have reportedly been in talks for months – Sanofi (NYSE:SNY) was also involved in discussions for Actelion, but was sidelined after J&J entered into exclusive negotiations with Actelion last […]

Filed Under: Featured, Mergers & Acquisitions, Pharmaceuticals, Respiratory, Wall Street Beat Tagged With: Actelion Pharmaceuticals, johnsonandjohnson, Sanofi-Aventis

J&J, Actelion still in talks despite Opsumit failure

January 23, 2017 By Sarah Faulkner

Actelion, Johnson & Johnson

Although Actelion (VTX:ATLN)’s Opsumit drug candidate missed its primary endpoint in a phase III trial for patients suffering from a deadly heart-lung condition, analysts reportedly concluded that the result is unlikely to have an impact on merger talks with Johnson & Johnson (NYSE:JNJ). The Swiss drugmaker’s trial involved 226 patients with Eisenmenger Syndrome, which causes untreated congenital heart […]

Filed Under: Cardiovascular, Clinical Trials, Featured, Mergers & Acquisitions, Respiratory Tagged With: Actelion Pharmaceuticals, johnsonandjohnson

  • Page 1
  • Page 2
  • Go to Next Page »

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS